<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053959</url>
  </required_header>
  <id_info>
    <org_study_id>ZSE-201902</org_study_id>
    <nct_id>NCT04053959</nct_id>
  </id_info>
  <brief_title>Artificial Intelligence Assisted Insulin Titration System</brief_title>
  <acronym>iNCDSS</acronym>
  <official_title>A Study to Assess the Effect and Safety of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients: A Single-center, Open-labeled, Parallel, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-labeled, parallel group, randomized controlled trial to access
      the effect and safety of the Artificial Intelligence Assisted Insulin Titration System in
      patients with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study enrolls 44 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment
      with insulin for at least 3 months. They are randomly allocated into 2 groups at a ratio of
      1:1 after screening for the inclusion and exclusion criteria. Patients in the Intervention
      group receive insulin regimen set by the AI assisted system and patients in Control group
      receive insulin regimen set by physicians. This study will be conducted in the Department of
      Endocrinology, Zhongshan Hospital,Fudan University and consist of a 7-day intervention
      period. Patient allocation will be stratified by HbA1c, BMI and previous total insulin
      doses.The primary endpoint is the percentage of time of sensor glucose measurements in
      targeted range (3.9-10 mmol/L) during the 7-days trial period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A paralle group, randomized, controlled study to assess the effect and safety of artificial intelligence assisted insulin dosage titration system on glucose control in type 2 diabetic patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The research assistants who collect study outcome data will be masked to participants' intervention assignment. In addition, the adjudicators for end-points will not be aware of study-group assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of time in target range</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The well-controlled blood glucose level is defined as the time of sensor glucose measurements in targeted range (3.9-10 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of time in which the blood glucose level is over 10 mmol/L</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The poor control of blood glucose level is defined as greater than 10 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of time in which the blood glucose level is below 3.9 mmol/L</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The hypoglycemia is defined as blood glucose level less than 3.9mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total insulin dose</measure>
    <time_frame>Each day during 7-day intervention</time_frame>
    <description>The total insulin dose is defined as daily insulin dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>AI Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial intelligence assisted insulin titration system group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physicians decided insulin titration group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AI assisted insulin system</intervention_name>
    <description>The patients receive the insulin regime set by AI assisted insulin titration system</description>
    <arm_group_label>AI Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician based insulin regime</intervention_name>
    <description>Patients receive the insulin regime recommended by physicians</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18-75 years old;

          -  Subjects who had been diagnosed with type 2 diabetes;

          -  Subjects who are on treatment with insulin for at least 3 months;

          -  HbA1c: 7.0%-11.0%.

        Exclusion Criteria:

          -  Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic
             hyperosmolar state;

          -  Subjects who change the insulin regimens during hospitalization;

          -  BMI â‰¥ 45kg/m2;

          -  Women who are pregnant or nursing;

          -  Subjects with severe cardiac, hepatic, renal or general diseases;

          -  Subjects with psychiatric disorders or impaired cognitive function;

          -  Subjects with severe edema, infections or peripheral circulation disorders;

          -  Patients treated with surgery during hospitalization;

          -  Subjects that are, in the judgement of the investigator, unlikely to comply with the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoying Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.</citation>
    <PMID>24002281</PMID>
  </reference>
  <reference>
    <citation>Wang T, Xu Y, Xu M, Wang W, Bi Y, Lu J, Dai M, Zhang D, Ding L, Xu B, Sun J, Zhao W, Jiang Y, Wang L, Li Y, Zhang M, Lai S, Wang L, Ning G. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study. Cardiovasc Diabetol. 2015 Feb 26;14:28. doi: 10.1186/s12933-015-0191-6.</citation>
    <PMID>25848699</PMID>
  </reference>
  <reference>
    <citation>Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013 Jun 21;13:602. doi: 10.1186/1471-2458-13-602.</citation>
    <PMID>23800082</PMID>
  </reference>
  <reference>
    <citation>Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282-8.</citation>
    <PMID>15920040</PMID>
  </reference>
  <reference>
    <citation>Oyer DS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Trippe BS; INITIATEplus Study Group. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med. 2009 Nov;122(11):1043-9. doi: 10.1016/j.amjmed.2008.12.026.</citation>
    <PMID>19854333</PMID>
  </reference>
  <reference>
    <citation>Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial. J Diabetes Investig. 2016 Jan;7(1):85-93. doi: 10.1111/jdi.12364. Epub 2015 May 25.</citation>
    <PMID>26816605</PMID>
  </reference>
  <reference>
    <citation>Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician. 2008 Apr;54(4):550-8.</citation>
    <PMID>18411384</PMID>
  </reference>
  <reference>
    <citation>Rigla M, GarcÃ­a-SÃ¡ez G, Pons B, Hernando ME. Artificial Intelligence Methodologies and Their Application to Diabetes. J Diabetes Sci Technol. 2018 Mar;12(2):303-310. doi: 10.1177/1932296817710475. Epub 2017 May 25.</citation>
    <PMID>28539087</PMID>
  </reference>
  <reference>
    <citation>Ashrafzadeh S, Hamdy O. Patient-Driven Diabetes Care of the Future in the Technology Era. Cell Metab. 2019 Mar 5;29(3):564-575. doi: 10.1016/j.cmet.2018.09.005. Epub 2018 Sep 27. Review.</citation>
    <PMID>30269984</PMID>
  </reference>
  <reference>
    <citation>Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124. doi: 10.1016/S2213-8587(16)30280-7. Epub 2016 Nov 9.</citation>
    <PMID>27836235</PMID>
  </reference>
  <reference>
    <citation>Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. N Engl J Med. 2018 Aug 9;379(6):547-556. doi: 10.1056/NEJMoa1805233. Epub 2018 Jun 25.</citation>
    <PMID>29940126</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

